BLOOMINGTON, Ind.--(BUSINESS WIRE)--Cook Medical will introduce its Stemulate™ Pooled Human Platelet Lysate cell culture media supplement at the 2014 International Society for Cellular Therapy meeting, April 23-26.
Stemulate provides researchers and cell therapy companies a cell expansion alternative to fetal bovine serum. Stemulate supports the expansion of multiple types of cells in vitro, including endothelial colony forming cells, fibroblasts, and mesenchymal stem cells (MSCs) from a variety of tissue sources.
“We know that researchers and companies working in cell therapy are passionate about developing the best clinical product,” said Brad King from the advanced lab products group at Cook Medical. “To take their idea from the lab to the patient, they are constantly looking for ways to improve their manufacturing. Based on our experience and feedback from customers, we’re confident Stemulate offers them a safe and consistent cell culture media supplement.”
Stemulate is produced in batches larger than 20 liters and the supply of human donor platelets is reliable and consistent. This helps to stabilize the product’s availability and pricing. For more information on Stemulate, visit www.stemulate.com.
About Cook Medical
Since 1963 Cook Medical has worked closely with physicians to develop technologies that eliminate the need for open surgery. Today we are combining medical devices, biologic materials and cellular therapies to help the world's healthcare systems deliver better outcomes more efficiently. We have always remained family-owned so that we have the freedom to focus on what we care about: patients, our employees and our communities. Find out more at www.cookmedical.com, and for the latest news, follow us on Twitter, Facebook and LinkedIn.